Ethinyl Estradiol, CAS# 57-63-6 is a widely used oral estrogen that can be found in most contraceptive products. The patent for Ortho Evra, which combines is ethinyl estradiol and norelgestromin is set to expire on November 20, 2015. Janssen markets the successful Ortho Evra patch, and the upcoming patent expiration is foreseen as an opportunity for the development of generic equivalents for this profitable product. As a form of birth control primarily, Ortho Evra is effectively a small skin patch with the same hormones as in oral birth control medications. Deemed 99% effective when used correctly, the birth control patch is worn for one week and then replaced on the same day of the week for three consecutive weeks. The fourth week is a patch-free week, as this is the week designated for the menses to occur. Side effects may include headache, rash at the patch site, cramping, nausea and breast tenderness. The convenience of the once weekly patch is ideal for many women, as today’s busy mom and wife needs a birth control to fit her busy lifestyle. Ten years ago Time Magazine named this birth control patch one of 2002’s “coolest inventions”, and profits have soared for the combination of this ethinyl estradiol and norelgestromin product since then.
Birth control is a primary method of delivery for ethinyl estradiol, either in the patch or pill formulation, but it is not it’s only use. Women experiencing menopause are often dosed with this female hormone and it is usually given to women who no longer produce the amount of estrogen they produced before menopause. Ethinyl estradiol is a very effective treatment for reducing common menopausal symptoms, such as hot flashes and bone loss.
On July 9, 2012 a statement regarding the safety and efficacy for the use of hormone replacement therapy and low dose estrogen, like ethinyl estradiol was made by a coalition of leading medical groups. The conclusion, which was posted as a new release from Dr. Margery Gass, executive director of the North American Menopause Society, concluded that “hormone-replacement therapy can be useful and safe for many women suffering from the symptoms of menopause.” The coalition was comprised of 15 medical groups including the North American Menopause Society, the Endocrine Society, the American Academy of Family Physicians and the the American Society for Reproductive Medicine. LGM Pharma is a provider of the API ethinyl estradiol, and offers continuous support to clients through the entire R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.